Jotbody is dedicated to offering nanobody discovery CRO services and nanobody-based research reagents of outstanding quality to the global scientific community.
Jotbody (HK) Limited is a biotechnology company founded in 2020 by a group of passionate scientists and a globally recognized board of directors with well-documented experience in biotherapeutics development and entrepreneurship. With dual sites in Hong Kong and Shenzhen (China), Jotbody is part of the two well-established biotech ecosystems that provide modern co-working labs, spaces, and world-class equipment. We are positioned to rise to the needs of our customers for many years to come.
We envision a world where high-quality R&D can be broadly accessed and generate significant benefits for patients and healthcare payers worldwide and our goal is to speed up research and discovery by providing the highest quality nanobodies at an outstanding value and with excellent customer and technical support. At Jotbody, we offer an extensive range of services including the discovery of nanobodies from immunized and naïve libraries, humanization, bioconjugation, multispecific nanobody development, computer-aided affinity maturation, Fc-fusion antibody development, sequencing, large-scale protein production, ELISA kits development, and antibody validation, as well as provide high-quality, timely, and cost-effective products to the global scientific community.
We are always on the lookout for innovative solutions that can address unmet needs. If you feel that your product aligns with our vision, we would be thrilled to explore the possibility of working together.